Travere Therapeutics Inc
NASDAQ:TVTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Travere Therapeutics Inc
NASDAQ:TVTX
|
US |
|
L
|
LVMH Moet Hennessy Louis Vuitton SE
DUS:MOH
|
FR |
|
M
|
Mirae Asset Securities Co Ltd
KRX:00680K
|
KR |
|
R
|
Rio Tinto PLC
XHAM:RIO1
|
UK |
|
T
|
Tripar Multivision Plus Tbk PT
IDX:RAAM
|
ID |
|
Ausgold Ltd
ASX:AUC
|
AU |
|
Addex Therapeutics Ltd
F:APE1
|
CH |
|
Ausgold Ltd
F:AU4
|
AU |
|
M
|
MEP Infrastructure Developers Ltd
NSE:MEP
|
IN |
|
Kering SA
F:PPXB
|
FR |
|
Clemondo Group AB (publ)
F:N170
|
SE |
|
Estika Tata Tiara Tbk PT
IDX:BEEF
|
ID |
|
Annaly Capital Management Inc
NYSE:NLY
|
US |
|
I
|
iNtRON Biotechnology Inc
KOSDAQ:048530
|
KR |
|
Q
|
Quanta Services Inc
F:QAA
|
US |
Intrinsic Value
Is TVTX undervalued or overvalued?
See the intrinsic value estimate for Travere Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
TVTX looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with TVTX’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Travere Therapeutics Does
Travere Therapeutics is a biotechnology company focused on rare kidney and liver diseases. It develops and sells prescription medicines for patients with conditions that are too small or specialized for big drug makers to chase through broad primary-care marketing. Its current business centers on specialty drugs such as treatments for IgA nephropathy and cystinuria, along with research programs for other serious rare diseases.
- Headquarters
- United States of America US
- Employees
- 497
- IPO date
- Jul 23, 2003
Revenue & Expenses Breakdown
Travere Therapeutics Inc
Earnings Waterfall
Travere Therapeutics Inc
The intrinsic value for Travere Therapeutics Inc (TVTX) under the Base Case is hidden USD.
Compared with the current market price of 52.99 USD, the stock appears hidden.